Use of SGLT2 inhibitors tied to lower dementia risk in older people with type 2 diabetes: Study

Canada: The new use of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with dipeptidyl peptidase 4 (DPP-4) inhibitors confers 20% lower dementia risk in older people with type 2 diabetes, a...

Related Keywords

Canada ,Toronto ,Ontario ,Nathan Herrmann ,Lisay Xiong ,Hugo Cogo Moreira ,Jennifers Rabin ,Refik Saskin ,Mario Masellis ,Bradleyj Macintosh ,Kristal Lanct ,Moirak Kapral ,Christa Wang ,Walter Swardfager ,Jodid Edwards ,Richardh Swartz ,Carina Iskander ,Baijur Shah ,University Of Toronto ,Association Of Sodium ,Population Based Cohort ,Diabetes Care ,Sglt2 Inhibitors ,Type 2 Diabetes ,Dementia ,Dpp 4 Inhibitors ,Older People ,Diabetes ,Medications ,Sodium Glucose Cotransporter 2 Inhibitors ,Canagliflozin ,Empagliflozin ,Dapagliflozin ,Dipeptidyl Peptidase 4 Inhibitors ,